Companies › Recursion Pharmaceuticals
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tak-733 (REC-4881) Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | Familial Adenomatous Polyposis | Jun 2027 |
| REC-1245 | – | Phase 1 | Unresectable | Oct 2028 |
| REC-7735 PIK3CA-H1047R inhibitor | PIK3CA | Phase 1 | Solid Tumors | Jan 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05552755 | Tak-733 (REC-4881) | Phase 1 | Familial Adenomatous Polyposis | Oncology | Jun 2027 |
| NCT06678659 | REC-1245 | Phase 1 | Unresectable | Oncology | Oct 2028 |
| NCT07819136 | REC-7735 | Phase 1 | Solid Tumors | Oncology | Jan 2031 |
Cash of $550m on 2026-09-30; operating cash outflow about $355m a year; runway about 19 months at that burn, to Apr 2028
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.